Login to Your Account

Curemark closes in on gut mechanism in autism with second phase III

By Marie Powers
News Editor

Monday, May 11, 2015

Privately held Curemark LLC launched an additional phase III trial of its chymotrypsin modulator, CM-AT, that will enroll a broad population of children with autism, ages 3 to 8, after a previous phase III of the compound met the endpoints in the same age group of children with autism.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription